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I. INTRODUCTION 
The 2017 Amended Sectoral Annex to the 1998 US-EU Mutual 
Recognition Agreement (“2017 Amended US-EU MRA”) became 
effective in November 2017, bridging a transatlantic regulatory gap 
between the United States (“US”) and the European Union (“EU”).1  
Although the Mutual Recognition Agreement (“MRA”) applies 
specifically to manufacturing facility inspections,2 it is a giant leap 
toward international harmonization of regulatory standards. 
This Note will first explore how the Food and Drug Administration 
(“FDA”) came into its regulatory authority in the United States.3  The 
current drug approval processes will be summarized with a focus on 
biological products and their link to manufacturing regulations.4  Next, 
 
 1. Press Release, EMA, EU-US Mutual Recognition of Inspections of Medicines 
Manufacturers Enters Operational Phase (Oct. 31, 2017), 
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/10/WC50023
7909.pdf [hereinafter EU-US Mutual Recognition of Inspections]. 
 2. Id. 
 3. See infra Part II.A. 
 4. See infra Part II.B. 
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this Note will take a comparative look at the European Medicines 
Agency (“EMA”) and their processes for drug market approval.5  Then, 
the 2017 Amended US-EU MRA and its implications will be examined.6  
Establishing the regulatory framework for drug approval will give 
context to the conclusion that the US’s biosimilar approval processes is 
lagging.  Biosimilar approval could be streamlined if the FDA utilizes 
the lessened burden on manufacturing regulation created by the 2017 
Amended US-EU MRA.  Working towards a similarly structured mutual 
recognition scheme for biosimilar products is a viable solution for the 
lagging US biosimilar market. 
II. THE REGULATORY FRAMEWORK FOR DRUG APPROVALS 
A. Milestones that Empowered the FDA’s Regulatory Role 
In response to consumer-protection concerns, Congress passed the 
Pure Food and Drugs Act in 1906 which created the FDA.7  At that time, 
there was no requirement for regulatory approval of any information 
before marketing. 8  The only requirement was for drugs to meet 
standards of strength and purity, enforced by the Bureau of Chemistry in 
the Department of Agriculture.9  The government had the burden of 
proof for showing that a drug’s label was false and misleading to take a 
product off the market.10 
In U.S. v. Johnson, the Supreme Court in 1911 ruled that “packages 
and bottles of medicine bearing labels that stated or implied that the 
contents were effective in curing cancer” were not misbranded within 
the meaning of Section 2 of the Food and Drugs Act, even with “the 
defendant well knowing that such representations were false.”11  This 
was because the Bureau of Chemistry of the Department of Agriculture12 
only determined whether the ingredients of a product were accurately 
represented.13  They had no power to ascertain a product’s medical 
 
 5. See infra Part II.C. 
 6. See infra Part III. 
 7. U.S. FDA, ABOUT FDA, https://www.fda.gov/AboutFDA/WhatWeDo/History/ (last 
updated Sept. 29, 2017). 
 8. MICHELLE MEADOWS, U.S. FDA, PROMOTING SAFE AND EFFECTIVE DRUGS FOR 
100 YEARS, 
https://www.fda.gov/downloads/AboutFDA/WhatWeDo/History/FOrgsHistory/CDER/UC
M586463.pdf (last updated June 18, 2009) 
 9. Id. 
 10. Id. 
 11. U.S. v. Johnson, 221 U.S. 488 (1911). 
 12. The Bureau of Chemistry of the Department of Agriculture acted as a proto-FDA 
before the FDA was established. See MEADOWS, supra note 8. 
 13. Johnson, 221 U.S. at 498. 
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effects.14  To overcome this hurdle, Congress enacted the Sherley 
Amendment in 1912 to prohibit labeling medicines with false 
therapeutic claims intended to defraud purchasers.15  However, the 
government still needed to prove an intent to defraud, which limited 
enforcement power.16  Finally, Congress passed the Federal Food, Drug, 
and Cosmetic Act (“FDCA”) of 1938.17  Under the FDCA, 
manufacturers now had to demonstrate their drug’s safety in their market 
approval application to the FDA.18 
Perhaps the most prominent event that effected change in 
regulatory enforcement was the thalidomide tragedy of the early 1960s.  
According to Max Sherman and Steven Strauss, “[n]o drug has done, or 
is likely to do, more toward the strengthening of existing drug laws in 
various countries and toward the creation of drug laws in others that 
lacked such legislation before the appearance of this drug in the 
marketplace.”19  Thalidomide was a widely used sleeping tablet in 
Europe.20  It was also used to treat nausea associated with pregnancy.21  
However, after widespread use adverse events started to trickle in, 
including “tingling hands, sensory disturbances, and later, motor 
disturbances and atrophy of the thumb.”22  These adverse events 
attracted the attention of Dr. Frances Kelsey, a physician and 
pharmacologist at the FDA.23  She was concerned about a drug’s effect 
on pregnancy due to her work with quinine, an anti-malarial drug with 
teratogenic effects.24  Because she had observed quinine’s adverse 
effects, she requested more data to show that using thalidomide was safe 
during pregnancy.25  Her diligence helped America avert a thalidomide-
induced birth defect crisis.  Across Europe, an alarming number of 
babies were being born with congenital birth defects.26  Unfortunately, 
it took years and widespread use to establish the relatedness between 
 
 14. Id. 
 15. MEADOWS, supra note 8. 
 16. Id. 
 17. Id. 
 18. Id. 
 19. Max Sherman & Steven Strauss, Thalidomide: A Twenty-Five Year Perspective, 31 
FOOD DRUG COSM. L.J. 458 (1986). 
 20. Id. at 460. 
 21. Id. 
 22. Id. at 460 (citing Helen B. Taussig, A Study of the German Outbreak of Phocomelia, 
180 (13) JAMA 1106 (1962)). 
 23. Sherman, supra note 19, at 461. 
 24. The use of teratogen indicates that a drug has the capacity under certain exposure 
conditions to produce abnormal development in an embryo or fetus.  U.S. FDA, REVIEWER 
GUIDANCE: EVALUATING THE RISKS OF DRUG EXPOSURE IN HUMAN PREGNANCIES (Apr. 
2005), https://www.fda.gov/downloads/Drugs/Guidances/ucm071645.pdf.   
 25. Sherman, supra note 19, at 461. 
 26. Id. at 463. 
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thalidomide and congenital birth defects.  Soon, the thalidomide story 
broke in the US and spurred public discourse on drugs and drug 
controls.27 
Even though it was not approved for use in the US, thalidomide still 
found its way to hundreds of pregnant women.28  The need for stronger 
enforcement of FDA regulations resulted in the 1962 Kefauver-Harris 
Drug Amendments to the Federal FDCA.29  The Investigational New 
Drug (“IND”) process was born, enacting procedural requirements 
during clinical investigation.30  Market approval from the FDA was now 
a requirement.31  Manufacturers now had to prove safety and substantial 
effectiveness for a product’s intended use through well-controlled 
studies.32  Good manufacturing practices were required and enforced 
through inspection.33  Adverse events were required to be reported.34  
Further, ethical considerations were implemented: study subjects were 
required to give informed consent, review boards approved protocols, 
and ethics committees monitored the risk-benefit of a patient’s 
participation in a trial.35 
Today, the FDA is the global gold standard for rigorous evaluation 
of safety, quality, and effectiveness before market approval. 36  The 
FDCA37 authorizes the FDA to inspect products already on the market.38  
The FDA also regulates manufacturing practices and evaluates new 
drugs, medical devices and food additives for safety and effectiveness 
before products are marketed to the public.39  If a product is determined 
to be unsafe or not FDCA-compliant, the FDA has the power to recall or 
seize products.40  In addition, the FDA issues standards for product 
 
 27. Id. 
 28. Id. 
 29. MEADOWS, supra note 8. 
 30. Sherman, supra note 19, at 463-64. 
 31. MEADOWS, supra note 8; see also 21 U.S.C. § 355(a) (West 2018) (requiring 
approval of an application for a new drug before introducing it into interstate commerce). 
 32. MEADOWS, supra note 8. 
 33. 21 U.S.C. § 355(n)(3) (West 2018). 
 34. 21 U.S.C. § 355(k)(3)(C) (requiring the establishment and maintenance of 
procedures for reporting data on serious adverse drug experiences). 
 35. U.S. FDA, INSTITUTIONAL REVIEW BOARDS FREQUENTLY ASKED QUESTIONS, 
https://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm (last visited Mar. 
29, 2018) [hereinafter INSTITUTIONAL REVIEW BOARDS FAQS]. 
 36. MEADOWS, supra note 8. 
 37. 21 U.S.C. §§ 301-399 (West 2018). Food, Drug and Cosmetic Act (FDCA), Practical 
Law Glossary Item 7-503-3134. 
 38. 21 U.S.C. § 341 (West 2018); 21 U.S.C. § 374(a)(1) (West 2018). 
 39. 21 U.S.C. § 355(a); 21 U.S.C. § 348(b) (West 2018). 
 40. 21 U.S.C. § 334(a)-(b); 21 U.S.C. § 350l(a)-(b) (West 2018); 21 U.S.C. § 360h(e) 
(West 2018). 
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labeling and other marketing communications, such as side effects and 
drug interactions that must be listed on pharmaceutical labels.41 
B. How Do Drugs Get Approved? 
Market approval of novel medical therapies weighs two important 
interests.42  First, the product must be safe and effective.43  Second, a 
thorough but expedient review process determines whether to grant 
public access to innovative therapies.44 
A drug manufacturer, also known as the sponsor,45 first identifies a 
medicinal product for commercialization.  If the product is a biologic 
that is also a “drug,” the biologic is subject to additional provisions of 
the FDCA.46  A “biologic,” or “biological product,” refers to a virus, 
therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or 
derivative, allergenic product, or protein applicable to the prevention, 
treatment, or cure of a disease or condition of human beings.47  
During preclinical development, the sponsor assesses the proposed 
product’s pharmacological activity and determines if it is reasonably 
safe for human use.48  If so, the sponsor files an Investigational New 
Drug (“IND”) application.49  Clinical trials are then initiated to prove a 
proposed drug’s safety and efficacy.50  Scientifically robust studies 
produce clinical data that are used to support a drug manufacturer’s 
application to market the drug, known as a New Drug Application 
(“NDA”).51  The NDA also contains proposed labeling, safety updates, 
drug abuse information, patent information, data from studies outside of 
the US, institutional review board compliance information, and 
directions for use. 52  
 
 41. See 21 U.S.C. §§ 343-343-3, 352, 360 (West 2018). 
 42. Gail A. Van Norman, Drugs and Devices: Comparison of European and U.S. 
Approval Processes, 1 JACC: BASIC TO TRANSLATIONAL SCI. 399, 400 (2016). 
 43. Id. 
 44. Id. 
 45. “Sponsor means a person who takes responsibility for and initiates a clinical 
investigation.” 21 C.F.R. § 312.3 (2017). 
 46. 42 U.S.C. § 262(j) (2017). 
 47. 42 U.S.C. § 262(i)(1). 
 48. U.S. FDA, INVESTIGATIONAL NEW DRUG (IND) APPLICATION, 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/InvestigationalNewDrugINDApplication/default.htm (last 
updated Oct. 5, 2017). 
 49. U.S. FDA, STEP 3: CLINICAL RESEARCH, 
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm (last updated Jan. 4, 
2018). 
 50. Id. 
 51. Id. 
 52. Id. 
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In the case of biologics, the sponsor submits a Biologics License 
Application (“BLA”).53  The BLA must include a full description of 
manufacturing methods; data establishing stability of the product 
through the dating period; sample(s) representative of the product; 
summaries of results of tests performed on the lot(s) represented by the 
submitted sample(s); and specimens of the labels, enclosures, and 
containers.54 
An FDA review team reviews preclinical and clinical data 
demonstrating a proposed drug’s safety and efficacy for intended use.  
After submission, the FDA review team55 categorically evaluates the 
data submitted and conducts clinical site inspections to supplement their 
review. 56  A decision to grant approval is made within six to ten 
months.57  
1. IND Requirements 
The IND application is necessary to commence clinical studies 
because it is the means through which a sponsor obtains an exemption 
from the FDA to ship the investigational drug to interstate clinical 
investigators.58  At a minimum, an application must include (1) full 
reports of investigations that demonstrate a drug’s safety and efficacy in 
use, (2) a full list of articles used as components of the drug, (3) a full 
statement of the drug’s composition, (4) a description of the methods 
used in, the facilities and controls used for, the manufacturing, 
processing, and packaging of the drug, (5) samples of the drug and 
articles used as components of the drug, and (6) proposed labeling for 
the drug.59 
 
 
 53. 21 C.F.R. § 601.2(a) (2017). 
 54. Id. 
 55. A review team consists of specialists representing different scientific fields.  A 
Project Manager coordinates the team’s activities and acts as the primary contact for the 
sponsor; a medical officer reviews clinical study information; a statistician interprets clinical 
trial designs and data; a pharmacologist reviews preclinical studies; a pharmakineticist 
evaluates a drug’s absorption, distribution, metabolism and excretion processes; and a chemist 
evaluates a drug’s chemical makeup.  STEP 3, supra note 49. 
 56. U.S. FDA, STEP 4: FDA DRUG REVIEW, 
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405570.htm (last updated Jan. 4, 
2018). 
 57. Id. 
 58. INVESTIGATIONAL NEW DRUG (IND) APPLICATION, supra note 48.  See also 21 
U.S.C. § 355(a) (2017) (“No person shall introduce or deliver for introduction into interstate 
commerce any new drug, unless an approval of an application filed…is effective with respect 
to such drug.”). 
 59. 21 U.S.C. § 355(b)(1) (2017). 
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2. Proving Safety and Efficacy: Clinical Trials of an 
Investigational New Drug 
An IND application must submit preclinical data from animal 
pharmacology and toxicology studies to demonstrate a drug’s safety and 
efficacy.60  It must also provide detailed protocols for proposed clinical 
studies.61 
The clinical investigation of a previously untested drug is divided 
into phases.62  In Phase 0 and 1 trials, a small population of healthy 
subjects are dosed with the investigational product.63  This serves to 
investigate the pharmacology of the drug in humans, detect side effects 
associated with increasing doses, and gain early evidence on 
effectiveness.64  These trials establish the product’s safety for human use.  
Phase 2 trials are next.  Hundreds of patients who are afflicted with the 
drug’s proposed indication are given incremental doses of the study 
drug.65  This phase will observe the efficacy of the drug for its intended 
purpose.66  Finally, Phase 3 trials increase the patient population.67  Up 
to thousands of patients are dosed with the investigational product to 
demonstrate efficacy while monitoring adverse reactions.68  Afterwards, 
a risk-benefit profile is developed to inform physician labelling.69 
a. Evaluating Safety by Monitoring Adverse Events 
Clinical trial progression is ultimately driven by the adverse events 
that emerge after using the drug product.  An “adverse event” means any 
untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered drug-related.70  “Serious adverse 
events” refer specifically to adverse events with outcomes such as death, 
a life-threatening event, inpatient hospitalization or prolongation of 
existing hospitalization, a persistent or significant disability, congenital 
 
 60. INVESTIGATIONAL NEW DRUG (IND) APPLICATION, supra note 48. 
 61. U.S. FDA, GUIDANCE FOR INDUSTRY: CONTENT AND FORMAT OF 
INVESTIGATIONAL NEW DRUG APPLICATIONS (INDS) FOR PHASE 1 STUDIES OF DRUGS, 
INCLUDING WELL-CHARACTERIZED, THERAPEUTIC, BIOTECHNOLOGY-DERIVED PRODUCTS 
(Nov. 1995), https://www.fda.gov/downloads/Drugs/. . ./Guidances/ucm074980.pdf. 
 62. 21 C.F.R. § 312.21 (2017). 
 63. AM. CANCER SOC’Y, WHAT ARE THE PHASES OF CLINICAL TRIALS?, 
https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-
to-know/phases-of-clinical-trials.html (last updated Feb. 7, 2017). 
 64. 21 C.F.R. § 312.21(a)(1). 
 65. See 21 C.F.R. §312.21(b). 
 66. 21 C.F.R. § 312.21(b). 
 67. See 21 C.F.R. §312.21(c). 
 68. Id. 
 69. Id. 
 70. 21 C.F.R. § 312.32(a). 
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birth defects, or an important medical event.71  A serious adverse event 
is reportable to the FDA in an “IND safety report” when there is a 
reasonable possibility of a causal relationship between the drug and the 
adverse event and if the event is unexpected.72  “Expectedness” refers to 
whether or not the event is listed in the investigator brochure as an 
identified risk described in the general investigational plan.73  Such 
reports must also be made known to participating investigators to whom 
the sponsor is providing the study drug.74 
Standardizing causality assessments is trickier.  Although causality 
is ultimately a clinical judgment, there are instances that allude to 
relatedness: (1) a single occurrence of an event that is uncommon and 
known to be strongly associated with drug exposure;75 (2) one or more 
occurrences of an event that is not commonly associated with drug 
exposure, but is other uncommon in the population exposed to the drug;76 
(3) an aggregate analysis of specific events observed that indicate an 
event may be occurring more frequently in the drug treatment group than 
a control group.77  
The sponsor company and the clinical site monitor the progress of 
each patient enrolled in the clinical trial. 78  They do this by selecting 
qualified investigators, providing them with the information needed to 
properly conduct the investigative study, monitor the study’s progress, 
and ensure that the FDA and all participating investigators are promptly 
informed of significant new adverse events or risk.79  Principal 
investigators lead clinical sites and review adverse events occurring in 
the clinical trial.80  Ultimately, the principal investigator assesses the 
investigational product’s causality to the adverse event.  An Institutional 
Review Board (“IRB”) reviews clinical protocols before a trial begins, 
monitors the progress, maintains records, and assure clinical testing 
meets ethical standards.81  A Data Monitoring Committee (“DMC”) will 
review patient data to ensure that a drug is demonstrating safety and 
 
 71. Id. 
 72. 21 C.F.R. § 312.32 (c)(1)(i) (2017). 
 73. See 21 C.F.R. §312.21(a). 
 74. 21 C.F.R. § 312.32(c)(1). 
 75. 21 C.F.R. § 312.32(c)(1)(i)(A). 
 76. 21 C.F.R. § 312.32(c)(1)(i)(B). 
 77. 21 C.F.R. § 312.32(c)(1)(i)(C). 
 78. U.S. FDA, INVESTIGATOR RESPONSIBILITIES — REGULATION AND CLINICAL 
TRIALS, (Nov. 13, 2013), 
https://www.fda.gov/downloads/training/clinicalinvestigatortrainingcourse/ucm378565.pdf. 
 79. Id. at 36. 
 80. Id. 
 81. INSTITUTIONAL REVIEW BOARDS FAQS, supra note 35. 
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efficacy.82  If the patient risk is too high, the trial could be terminated.83  
If the drug is not demonstrating efficacy, then it is meaningless to 
continue the study and deprive patients the standard of care, if available. 
b. Proving Efficacy 
For marketing approval, companies must present substantial 
evidence that the investigational product has a clinically meaningful 
effect.84  Patients participate in clinical studies seeking improved 
survival, detectable benefits such as symptom relief, or decreased 
chances of developing a disease complication (e.g. stroke).85  To show 
efficacy, clinical trials should have an endpoint with a measurable 
outcome.86  Objective endpoints include quantitative measurements of 
biochemical parameters, survival, disease exacerbation, or important 
medical events (e.g. stroke).  Subjective measures as endpoints evaluate 
outcomes such as symptom scores and quality-of-life evaluations.87  
Ideally, the endpoints will prove efficacy by demonstrating a 
statistical significance between two treatments or strategies being 
compared with respect to the endpoint measure.88  
3. Demonstrating Quality and Potency: Manufacturing Practices 
The FDA regulates pharmaceutical quality and manufacturing 
standards with a series of continuously updated guidance documents 
published as the Current Good Manufacturing Practice (“CGMP”) 
Standards.89  CGMPs generally outline systems for proper design, 
monitoring, and control of manufacturing processes and facilities.90  This 
 
 82. U.S. FDA, ESTABLISHMENT AND OPERATION OF CLINICAL TRIAL DATA 
MONITORING COMMITTEES FOR CLINICAL TRIAL SPONSORS, 
https://www.fda.gov/RegulatoryInformation/Guidances/ucm127069.htm (last visited Mar. 
29, 2018). 
 83. Id. 
 84. Eugene J. Sullivan, U.S FDA, CLINICAL TRIAL ENDPOINTS 3, 
https://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM337268.
pdf (last visited Jan. 30, 2018). 
 85. Id. 
 86. See Joseph Spahn, Clinical Trial Efficacy: What Does it Really Tell You?, 112 J. OF 
ALLERGY & CLINICAL IMMUNOLOGY 102 (2003). 
 87. Id. 
 88. See OFF. OF BEHAV. & SOC. SCI. RES., CLINICAL TRIALS: ENDPOINTS, 
http://www.esourceresearch.org/eSourceBook/ClinicalTrials/4Endpoints/tabid/200/Default.a
spx (last visited Jan. 30, 2018). 
 89. See U.S. FDA, PHARMACEUTICAL QUALITY/MANUFACTURING STANDARDS 
(CGMP), 
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064
971.htm (last updated Oct. 6, 2017). 
 90. U.S. FDA, FACTS ABOUT THE CURRENT GOOD MANUFACTURING PRACTICES 
(CGMPS), 
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includes establishing strong quality management systems, obtaining 
appropriate quality raw materials, establishing robust operating 
procedures, detecting and investigating product quality deviations, and 
maintaining reliable testing laboratories.91  Regulation adherence 
ensures patient safety. Failure to comply with CGMP regulations results 
in “adulterated products” that could be subject to recall—or in cases of 
noncompliance with a recall request, an injunction and product seizure.92  
Information pertaining to the composition, manufacturing, stability, and 
controls used in drug manufacturing is assessed to ensure that the 
sponsor can adequately produce and supply consistent batches of the 
drug. 93 
C. The EMA’s Regulatory Role 
The European Medicines Agency (“EMA”) oversees the European 
medicines regulatory network through a collaboration between the 
European Commission (EC) and regulatory authorities in European 
Economic Area (“EEA”) countries.94  Marketing authorization—that is, 
the legal decision to grant, suspend or revoke a marketing authorization 
for any medicine—in the EU falls under the purview of the EC.95  
Market-authorization holders (i.e. biopharmaceutical companies) submit 
single market-authorization applications for the EMA to evaluate.96  In 
this sense, the EMA’s centralized authorization process is similar in 
function to the FDA, which oversees all drug approvals in the United 
States.  Under the centralized process, the EMA carries out scientific 
assessment of the application and recommends approval.97  
Authorization decisions are made in the interest of public health “on the 
basis of objective scientific criteria of quality, safety and efficacy of the 
medicinal product concerned, to the exclusion of economic and other 
 
https://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/ucm169105.htm 
(last updated Oct. 6, 2017). 
 91. Id. 
 92. Id. 
 93. Id. 
 94. EUROPEAN MED. AGENCY, HISTORY OF THE EMA, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000
628.jsp (last visited Jan. 20, 2018). 
 95. EUROPEAN MED. AGENCY, WHAT WE DO, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000
091.jsp (last visited Jan. 20, 2018). 
 96. See EUROPEAN MED. AGENCY, LEGAL FRAMEWORK, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000
127.jsp (last visited Jan. 20, 2018). 
 97. WHAT WE DO, supra note 95. 
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considerations.”98  “Every member state of the EU is represented on the 
EMA committee for Medicinal Products.”99  
The centralized plan aimed to reduce the cost for drug companies 
to obtain approvals and eliminate protectionist tendencies of member 
nations that would otherwise favor domestic products.100  Moreover, the 
EMA and Member States cooperate and share expertise in assessing new 
medicines and safety information through reviewing reported side 
effects, overseeing of clinical trials, and conducting of manufacturing 
inspections.101  Functionally, the EMA is a conglomerate of its Member 
States’ regulatory authorities.  As such, the EMA has several routes to 
drug approval beyond the centralized procedure. 
1. EU Authorization through National Authorization 
Of course, regulatory authorities of EU Member States can also 
authorize products nationally.  The local regulatory authority would be 
responsible for authorizing medicines not passing through the 
centralized procedure.102  Here, the national regulatory authority would 
be responsible for verifying that manufacturers and importers of 
medicinal products coming from outside the EU follow EU-established 
manufacturing standards.103 
2. EU Authorization through Mutual Recognition 
The EMA is perhaps the “best-established example of regulatory 
cooperation between medicines authorities.”104  Within the EMA 
network, Directive 2004/27/EC outlines a mutual recognition procedure 
 
 98. Regulation (EC) 726/2004 of the European Parliament and of the Council: Laying 
Down Community Procedures for the Authorisation and Supervision of Medicinal Products 
for Human and Veterinary Use and Establishing a European Medicines Agency, 2004 O.J. (L 
136), 1, 4 https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-
1/reg_2004_726/reg_2004_726_en.pdf [hereinafter Regulation 726/2004/EC]. 
 99. Norman, supra note 42. 
 100. Id. 
 101. EUROPEAN MED. AGENCY, THE EUROPEAN REGULATORY SYSTEM FOR MEDICINES: 
A CONSISTENT APPROACH TO MEDICINES REGULATION ACROSS THE EUROPEAN UNION,  
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2014/08/WC500171674.p
df (last visited Jan. 20, 2018). 
 102. EUROPEAN MED. AGENCY, NATIONAL COMPETENT AUTHORITIES (HUMAN), 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_00
0155.jsp&mid=WC0b01ac0580036d63 (last visited Jan. 20, 2018). 
 103. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 
2001 on the Community Code Relating to Medicinal Products for Human Use, art. 20, 2001 
O.J. (L 311). 
 104. Riccardo Luigetti, Peter Bachmann, Emer Cooke & Tomas Salmonson, 
Collaboration, Not Competition: Developing New Reliance Models, 30 WHO DRUG INFO. 
558, 559 (2016). 
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for EU market authorization.105  Medicines that already received 
authorization in one EEA Member State may apply for mutual 
recognition in other Member States.106  The applicant will request one 
Member State to be the “reference Member State” to evaluate the 
medicine and decide whether to grant authorization.107  The other 
Member States, the “concerned Member States,” must adopt a decision 
that conforms with the approved assessment report from the reference 
Member State, the summary of product characteristics, and the labelling 
and package leaflet as approved.108 
3. EU Authorization through the Decentralized Procedure 
Directive 2004/27/EC outlines the decentralized procedure for 
marketing authorization.109  Though very similar to the mutual 
recognition procedure, the decentralized procedure is enacted for 
medicines that have not previously received marketing authorization.110  
Like the mutual recognition procedure, it relies on national authorization 
in one Member State to obtain mutual recognition.111  Under the 
decentralized procedure, identical dossiers are submitted to all Member 
States where marketing authorization is sought.112  Effectively, this 
process joins concerned Member States at an earlier stage of evaluation 
to minimize disagreements when adopting mutual recognition of the 
novel therapy. 
4. Timeline Efficiency Compared to the FDA 
The issue is then whether shared expertise framework of the EMA 
approval process creates any efficiencies.  Between 2011 and 2015, the 
FDA approved 170 new therapeutic agents compared to the EMA which 
approved 144.113  The therapeutic areas of the approvals were similar in 
the two agencies, although the FDA approved more orphan drugs than 
by the EMA (43.5% vs. 25.0% of the approved agents).114  The total 
 
 105. See Directive 2004/27/EC, art. 28, 2004 O.J. (L 136/44). 
 106. Id. at art. 28. 
 107. Id. 
 108. Id. 
 109. See id. at arts. 27-32. 
 110. EUROPEAN COMM’N, AUTHORISATION PROCEDURES — THE DECENTRALISED 
PROCEDURE, https://ec.europa.eu/health/authorisation-procedures-decentralised_en (last 
visited Jan. 20, 2018). 
 111. Id. 
 112. Directive 2004/27/EC, art. 28, 2004 O.J. (L 136/44). 
 113. Nicholas S. Downing, Audrey D. Zhang & Joseph S. Ross, Regulatory Review of 
New Therapeutic Agents — FDA versus EMA, 2011-2015, 376 NEW ENG. J. MED. 1386 
(2017). 
 114. Id. 
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review times did vary based on therapeutic areas; the FDA had shorter 
times for cancer and hematologic disease treatments as well as orphan 
drugs.115  However, on average FDA review periods were sixty days 
shorter than those by the EMA.116 
D. The Pathway for Approval of Biosimilars in the US and EU 
A “biosimilar” is a biological product that is highly similar to a 
reference product except for minor differences in clinically inactive 
components.117  In the US, biologic product licensing and regulation is 
governed by the Public Health Service Act (“PHSA”).118  The Biologics 
Price Competition and Innovation Act (“BPCIA”) of 2009 passed as part 
of the Affordable Care Act in 2010.119  The BPCIA created an 
abbreviated pathway for biosimilar or interchangeable products 
licensing by relying on the safety and efficacy data in an FDA-approved 
reference product.120  Essentially, BPCIA enables a biosimilar biological 
product to be licensed based on less than a full complement of product-
specific preclinical and clinical data.121 
Genetically engineering cells to produce biologics is a complex 
process that drives up the costs of biological products.122  BPCIA’s aim 
was to increase access to treatment and to lower health care costs.123  The 
EU had implemented a similar abbreviated approval pathway for 
biosimilars in 2005.124  Greater availability of biosimilar products, 
especially in low-income EU countries, influenced national drug 
 
 115. Id. 
 116. Id. 
 117. 42 U.S.C. § 262(i)(2)(A). 
 118. Biological products are approved and regulated under Section 351 of the Public 
Health Service Act, which is codified at 42 U.S.C. § 262. 
 119. Darryl Woo, Erin A. Thomson, Janice Ta & Wendy Wang, Amgen v Sandoz: 
Marketing Exclusivity Under the BPCIA, LIFE SCI. INTELL. PROP. REV. (2016). 
 120. Id. 
 121. LEAH CHRISTL, U.S. FDA, OVERVIEW OF THE REGULATORY FRAMEWORK AND 
FDA’S GUIDANCE THE DEVELOPMENT AND APPROVAL OF BIOSIMILAR PRODUCTS IN THE US 
4, 
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
OncologicDrugsAdvisoryCommittee/UCM561565.pdf (last visited Jan. 30, 2018). 
 122. Practical Law Intellectual Property & Technology, What You Need to Know About 
the BPCIA, Practical Law Legal Update 5-590-4543 (Dec. 2, 2014) (West). 
 123. Id. 
 124. Martin Schiestl, Markus Zabransky, & Fritz Sörgel, Ten Years of Biosimilars in 
Europe: Development and Evolution of the Regulatory Pathways, 11 DRUG DESIGN, DEV. & 
THERAPY 1509 (2017). 
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reimbursement systems.125  This resulted in increased access to effective 
treatment because of reduced costs to patients.126 
The EU pathway for the approval of biosimilars is comparable to 
the FDA’s process.  The Committee for Medicinal Products for Human 
Use (“CHMP”) under the EMA issues guidelines for the biosimilar 
regulatory framework.127  The CHMP provides initial assessments for 
marketing authorization of new medicines that are ultimately approved 
centrally by the EMA.128 
1. Demonstrating Quality of the Proposed Biosimilar 
Biosimilars, like all medicinal products approved in the EU and US, 
must demonstrate pharmaceutical quality.129  But unlike traditional 
pharmaceuticals and their respective generics, biologics are not able to 
be manufactured as perfect equivalents.130  Traditional pharmaceutical 
drugs are chemically synthesized small molecules.131  In contrast, 
biologics are complex macromolecular structures consisting of 
proteins.132  Biologics have inherent variability because they are 
produced via living cells, which can modify protein structure based on 
its growth environment.133  However, biologics product quality is not 
affected so long as the critical attributes of the biologic’s structure is 
carefully monitored and retained.134 
 
 125. The reimbursement criteria for biosimilars were similar to those for other generic 
products in that the pricing policies for biosimilar medicines was set in relation to the price of 
the originator.  See Pawl Kawalec et al., Pricing and Reimbursement of Biosimilars in Central 
and Eastern European Countries, 8 FRONTIERS IN PHARMACOLOGY (June 2017), 
https://www.frontiersin.org/articles/10.3389/fphar.2017.00288/full.  
 126. The high price of original drugs limits access to treatment, especially in low-income 
Central and Eastern European countries.  Id. 
 127. The legal basis for similar biological applications can be found in Regulation 
726/2004/EC, O.J. (L 136/1), art. 6. 
 128. EUROPEAN MED. AGENCY, GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL 
PRODUCTS, CHMP/437/04 (Oct. 30, 2005). 
 129. EUROPEAN MED. AGENCY, BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR 
HEALTHCARE PROFESSIONALS 10, 
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.p
df (last visited Jan. 30, 2018). 
 130. U.S. FDA, BIOSIMILAR AND INTERCHANGEABLE PRODUCTS, 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm#
biological (last updated Oct. 23, 2017). 
 131. BIOTECHNOLOGY INNOVATION ORG., HOW DO DRUGS AND BIOLOGICS DIFFER?, 
https://www.bio.org/articles/how-do-drugs-and-biologics-differ (last visited Apr. 28, 2018). 
 132. Id. 
 133. Arnold G. Vulto & Orlando A. Jaquez, The Process Defines the Product: What 
Really Matters in Biosimilar Design and Production?, 56 RHEUMATOLOGY iv14 (Aug. 30, 
2017). 
 134. Id. 
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The FDA grants licensure for biosimilars in a process analogous to 
the aforementioned NDA process.135  In the Biologics License 
Application (“BLA”), the proposed biosimilar must include analytical 
studies demonstrating that the product is highly similar to the reference 
product, minus inactive components.136  Animal studies are included to 
assess toxicity.137  Clinical studies test safety, purity, and potency of the 
product for its intended use.138  Furthermore, the route of administration, 
dosage form, and strength of the biosimilar must be same as those of the 
reference product.139  Finally, the manufacturing practices used to 
produce the biosimilar must meet standards to ensure a safe, pure, and 
potent product.140  
The FDA, through its Center for Biologics Evaluation and Research 
(“CBER”),141 “inspects manufacturing plants before it approves 
products, and thereafter, on a regular basis” to ensure that biological 
products are confirming to laws and regulations.142  Companies must 
report to the CBER within forty-five days of awareness of any biological 
product deviations from good manufacturing practice that may affect the 
safety, purity, or potency of a distributed product.143  This includes 
testing, processing, packing, labeling, or storage, or with the holding or 
distribution of a licensed biological product. 144  Regulatory approvals of 
biologics are more demanding than regulatory approvals of general drug 
products.  More studies are required to show product quality because of 
the variability expected in manufacturing biologic products. 
2. Comparative Studies to Establish High Similarity and 
Interchangeability 
A biosimilar product must have no clinically meaningful 
differences between the reference biologic product in terms of safety, 
purity, and potency of the product.145  To demonstrate that the active 
substance of the proposed biosimilar is highly similar to the reference 
 
 135. The Food and Drug Administration Modernization Act of 1997 created uniformity 
between the NDA and BLA approval processes. 
 136. 42 U.S.C. § 262(k)(2)(A). 
 137. Id. 
 138. Id. 
 139. Id. 
 140. Id. 
 141. U.S. FDA, CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) 
RESPONSIBILITIES QUESTIONS AND ANSWERS, 
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBE
R/ucm133072.htm (last updated Aug. 5, 2015). 
 142. Id. 
 143. 21 C.F.R. § 606.171 (2017). 
 144. Id. 
 145. 42 U.S.C. § 262(i)(2)(B). 
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medicine, comprehensive comparative studies are first conducted with 
the reference medicine.146  Extensive biochemical and biophysical 
analytical methods are used to confirm the primary structure and protein 
modification that may result from protein biosynthesis.147  If the 
proposed biosimilar is structurally comparable to the reference 
medicine, the positive benefit-risk profile of the reference medicine is 
conferred upon the biosimilar.148  The biosimilar can then quickly move 
through the approval process by relying on the efficacy and safety data 
of the reference biologic.149 
The next step is to conduct comparative clinical studies in human 
subjects.  “The aim of studies in humans is not to demonstrate safety and 
efficacy in patients, as these have already been established for the 
reference medicine.”150  Rather, the studies ensure that the biosimilar’s 
pharmacokinetics and pharmacodynamics (describing exposure-
response relationships) conforms with the reference product. 151  
“Interchangeable products” are biosimilars that need to meet 
additional requirements. 152  As its name suggests, an interchangeable 
product should be substitutable for the reference product without 
prescriber involvement; switching back and forth between an 
interchangeable product and a reference product should not impact the 
safety nor efficacy.153  For interchangeable products, the FDA requires a 
transition study to show that there are no increases in safety events 
between a patient cohort that stays on the reference product compared to 
the cohort that switches to the biosimilar. 154  Though the 
interchangeability pathway is not required by the FDA, 
interchangeability is a prerequisite for automatic substitution at the 
 
 146. BIOSIMILAR AND INTERCHANGEABLE PRODUCTS, supra note 130. 
 147. Elizabeth Hyland et al., Comparison of the Pharmacokinetics, Safety, and 
Immunogenicity of MSB11022, a Biosimilar of Adalimumab, with Humira® in Healthy 
Subjects, 82 BRITISH J. OF CLINICAL PHARMACOLOGY 983 (2016). 
 148. Id. 
 149. A manufacturer need only show that its biosimilar product is highly similar and has 
no clinically meaningful differences from the approved reference product (which already has 
a full profile nonclinical and clinical data). Patient access is much quicker because redundant 
clinical trials are not necessary. U.S. FDA, BIOSIMILAR DEVELOPMENT, REVIEW, AND 
APPROVAL, 
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapprove
d/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580429.htm#process 
(last updated Oct. 23, 2017). 
 150. BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR HEALTHCARE PROFESSIONALS, 
supra note 129. 
 151. CHRISTL, supra note 121. 
 152. BIOSIMILAR AND INTERCHANGEABLE PRODUCTS, supra note 130. 
 153. Id. 
 154. See id. 
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pharmacy level.155  Pharmacy level interchangeability allows drug 
substitution without input from a doctor.  Pharmacy-level substitution is 
already the case for traditional generics.156  To save costs, insurance 
companies could exclusively cover interchangeable biosimilars when 
one is available in lieu of paying full price for the original biologic.157 
E. A New Drug is Approved: The Post-Market Landscape 
Post-marketing studies allow monitoring of known risks.  
Furthermore, because the drug is now available to a larger number of 
patients treated over a longer period, detection of rare adverse drug 
reactions may be made from the aggregate data.  For example, the 
congenital birth defects linked to thalidomide were not discovered until 
after mass-market use.158 
Experiences which are both “serious”159 and “unexpected”160 must 
be reported to the FDA within fifteen calendar days.161  All other adverse 
drug experiences for NDA-approved products are compiled into periodic 
reports for the FDA quarterly or annually, depending on how long the 
drug has been approved.162  Additionally, manufacturers proactively 
seek information about their products from a variety of sources: 
scientific literature, commercial marketing experience, 
epidemiological/surveillance studies.163  Failure to establish and 
maintain records and make reports may result in the FDA withdrawing 
approval which would prohibit continued marketing of the drug.164 
Since comprehensive clinical testing is often not required, post-
market safety monitoring is particularly important for biosimilars 
because of the limited clinical data available at the time of approval.165 
 
 155. Id. 
 156. Lauren F. Friedman, An Innovation that Could Transform the Drug Industry Faces 
a Major Hurdle, BUS. INSIDER (Apr. 29, 2015), http://www.businessinsider.com/biosimilars-
bioequivalence-and-interchangeability-2015-4. 
 157. Id. 
 158. As discussed supra Part II.A, thalidomide was widely used across Europe before an 
alarming number of congenital birth defects were associated with the drug. 
 159. See 21 C.F.R. § 312.32(a). 
 160. Id. 
 161. 21 C.F.R. § 314.80(c)(1)(i) (2017). 
 162. 21 C.F.R. § 314.80(c)(2)(i). 
 163. 21 C.F.R. § 314.80(b). 
 164. 21 C.F.R. § 314.80(k). 
 165. Donna M. Gitter, Informed by the European Union Experience: What the United 
States Can Anticipate and Learn from the European Union’s Regulatory Approach to 
Biosimilars, 41 SETON HALL L. REV. 559, 582-83 (2011). 
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F. US-EU Harmonization: A Mutual Recognition Agreement 
A Mutual Recognition Agreement (“MRA”) is an agreement 
between two or more countries to recognize a specific process or 
procedure in the other country.166  Effectively, MRAs are trade 
agreements that encourage greater international harmonization of 
compliance standards and consumer protection.167  MRAs facilitate 
market access in an age where the manufacture and distribution of 
modern medicines is increasingly globalized168 by strengthening use of 
each agency’s drug inspection expertise and resources, resulting in 
“greater efficiencies for both regulatory systems and provide a more 
practical means to oversee the large number of drug manufacturing 
facilities outside of the US and EU.” 169  
In 1998, the US and EU entered into a MRA with provisions 
concerning current Good Manufacturing Practices, which were never 
fully implemented.170  For the MRA to operate, the US and EU needed 
“reassurance that the GMP inspectorates on both sides have the 
capability, capacity and procedures in place to supervise manufacturers 
of medicines at an equivalent level.”171  As such, since 2014, teams from 
EU national authorities,172 the European Commission, EMA, and the 
FDA have audited and assessed the respective supervisory systems.173  
Such assessments included internal audits of each country’s processes, 
workforce skills, compliance with local laws and guidelines.174  
Effective November 2017, US and European regulators agreed on 
mutual recognition of inspections of medicines conducted in their 
respective territories.175  This MRA would allow the US and EU to rely 
on each other’s good manufacturing practices system, share information 
 
 166. U.S. FDA, FREQUENTLY ASKED QUESTIONS / THE MUTUAL RECOGNITION 
AGREEMENT 1 (July 2017), 
https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOpera
tionsandPolicy/UCM544394.pdf [hereinafter FAQ / THE MUTUAL RECOGNITION 
AGREEMENT]. 
 167. EUROPEAN MED. AGENCY, MUTUAL RECOGNITION AGREEMENTS, 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_00
1843.jsp&mid=WC0b01ac058005f8ac (last visited Jan. 30, 2018) [hereinafter MUTUAL 
RECOGNITION AGREEMENTS]. 
 168. Luigetti et al., supra note 104. 
 169. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166. 
 170. Id. 
 171. EU-US MUTUAL RECOGNITION OF INSPECTIONS, supra note 1. 
 172. For a full list of each Member State’s national regulatory authority, see EUROPEAN 
MED. AGENCY, NATIONAL COMPETENT AUTHORITIES (HUMAN), 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_00
0155.jsp (last visited Jan. 30, 2018). 
 173. EU-US MUTUAL RECOGNITION OF INSPECTIONS, supra note 1. 
 174. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166. 
 175. EU-US MUTUAL RECOGNITION OF INSPECTIONS, supra note 1. 
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on inspections and quality defects, and waive batch testing of products 
on import.176  “The 2017 Amended Sectoral Annex to the 1998 US-EU 
MRA allows the FDA and the EU inspectorates to use inspection reports 
and other related information obtained during drug manufacturing 
facility inspections, whether conducted by an EU inspectorate or by the 
FDA, to help determine whether a facility is manufacturing high quality 
drugs.”177 
Of note, the MRA stipulates that the FDA will conduct an 
individual assessment of each EU Member State’s regulatory authority 
before the MRA is effective.178  Also, the FDA or EU reserve the ability 
to require further inspections as deemed necessary.179 
With the enactment of the 2017 Amended US-EU MRA, 
duplicative inspections should be the exception.180  This will allow the 
FDA and EMA to allocate resources toward addressing higher public 
health risks thereby benefiting patient care. 181 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 176. MUTUAL RECOGNITION AGREEMENTS, supra note 167. 
 177. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166. 
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III. IF BPCIA WAS SUPPOSED TO SPEED THINGS UP, WHY IS 
BIOSIMILAR APPROVAL STILL SLOW? 
A. The United States is Trailing the European Union in Biosimilar 
Approvals 
The first FDA-licensed biosimilar was Zarxio, approved in 2015.182 
In 2016, the FDA only licensed three new biosimilars.183  However, 2017 
was a banner year for biosimilar approvals by the FDA. The FDA 
approved five biosimilars in 2017 for a total of nine approved overall.184  
This update may be credited to the FDA’s January 2017 release of a 
long-awaited draft guidance on interchangeability considerations.185  
Previously, the FDA was providing one-on-one advice to sponsors about 
data expected to demonstrate interchangeability.186  The draft guidance, 
“Considerations in Demonstrating Interchangeability With a Reference 
Product,” clarifies expectations.187  However, the guidance document 
does recommend that the comparator used in switching studies be a US-
licensed reference product instead of a foreign-approved product.188 
Although this guidance is specifically for interchangeable products, it 
still provides insight into the FDA’s standards for biosimilar approval. 
The US trails behind the EMA’s fifty-four approved biosimilars, 
which represent sixteen unique biologics.189  The chart below 
 
 182. Sue Sutter, Biosimilars in 2017: Crowded US FDA Review Queue, Key Legal 
Decisions, PINK SHEET PHARMA INTELL. (Jan. 24, 2017), 
https://pink.pharmaintelligence.informa.com/PS119882/Biosimilars-In-2017-Crowded-US-
FDA-Review-Queue-Key-Legal-Decisions; U.S. FDA, BIOSIMILAR PRODUCT 
INFORMATION, 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm. 
 183. Id. 
 184. Jacob F. Siegel & Irena Royzman, US Biosimilar Approvals Soar in 2017, 
BIOLOGICS BLOG (Dec. 18, 2017), https://www.biologicsblog.com/us-biosimilar-approvals-
soar-in-2017. 
 185. The draft guidance formally lays out FDA expectations for interchangeability. This 
has standardized the process which previously relied on one-on-one communications between 
the agency and sponsor. Sutter, supra note 182. 
 186. Sutter, supra note 182. 
 187. See U.S. FDA, DRAFT GUIDANCE FOR INDUSTRY: CONSIDERATIONS IN 
DEMONSTRATING INTERCHANGEABILITY WITH A REFERENCE PRODUCT, (Jan. 2017), 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan
ces/UCM537135.pdf. 
 188. Id. at 15.  See also infra Part V.C for discussion on how this requirement could be 
superseded by the EU-US Mutual Agreement. 
 189. As of Dec. 30, 2018 there are fifty-three approved biosimilars and one approval 
pending. See EUROPEAN MED. AGENCY, LIST OF BIOSIMILARS APPROVED BY THE EMA, 
http://www.ema.europa.eu/ema/ (select “Search” under “Medicines” tab; then select 
“Human” category; then select “Biosimilars” under medicine type) (last visited Dec. 30, 2018) 
[hereinafter LIST OF BIOSIMILARS APPROVED BY THE EMA]. 
 224 SANTA CLARA LAW REVIEW [Vol:59 
demonstrates that the EU has a wide breadth of available biosimilars.  
For some active substances, the EU has approved multiple biosimilars. 
Table 1: Number of Biosimilars Approved in the EMA v. FDA 
Active 
Substance Brand Name190 
# Approved 
by EMA191 
# Approved 
by FDA192 
adalimumab Humira® 8 3 
bevacizumab Avastin® 1 1 
enoxaparin 
sodium Lovenox
® 2 0 
epoetin alfa Epogen® 3 1 
epoetin zeta Retacrit® 2 0 
etanercept Enbrel® 2 1 
filgrastim Neupogen® 7 2 
follitropin alfa Gonal-f® 2 0 
infliximab Remicade® 4 3 
insulin 
glargine Lantus
® 3 0 
insulin lispro Humalog® 1 0 
pegfilgrastim Neulasta® 5 2 
rituximab Rituxan® 6 1 
somatropin Norditropin® 1 0 
teriparatide Forteo® 2 0 
trastuzumab Herceptin® 4 2 
 TOTAL 53 16 
 
The FDA and EMA have nine approved biosimilars in common.193  
Three biosimilars are exclusively approved in the US; Ixifi (infliximab), 
 
 190. To identify brand name from active substance, see Drugs A-Z List, RXLIST, 
https://www.rxlist.com/drugs/alpha_a.htm (last visited Nov. 3, 2018). 
 191. LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189. 
 192. U.S. FDA, BIOSIMILAR PRODUCT INFORMATION, 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAppr
oved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580432.htm. 
 193. The nine approved biosimilars in common are: Amgevita (adalimumab), Cyltezo 
(adalimumab), Hyrimoz (adalimumab), Mvasi (bevacizumab), Retacrit (epoetin alfa), Erelzi 
(etanercept), Zarzio (filgrastim), Nivestym (filgrastim), and Inflectra (infliximab)). Compare 
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Renflexis (infliximab), and Ogivri (trastuzumab) are not yet approved 
by the EMA as of December 2018.  However, for each of these, at least 
one biosimilar with the same active substance is authorized for sale in 
the EU market.  Seven active substances approved in the EMA have not 
yet been approved by the FDA. 
Table 2 below shows that the EMA has been approving biosimilars 
for over a decade, the first approved in 2006.  In contrast, the first FDA-
approved biosimilar was in 2015.194  The EMA approval dates also show 
that the EMA approves more biosimilars every year.195  The FDA is also 
increasing its approval rate, though with only three years’ worth of 
data—and pending patent litigation and comments on the FDA’s 
released interchangeability guidance document—it is difficult to 
determine if this approval trend will continue.196 
Table 2: Biosimilar Approval Dates in the EMA v. FDA 
Active 
Substance 
Brand 
Name197 
Biosimilar 
Name 
EMA 
Approved198 
FDA 
Approved199 
adalimumab Humira® 
Amgevita Mar-2017 Sep-2016 
Cyltezo Nov-2017 Aug-2017 
Halimatoz  Jul-2018 - 
Hefiya Jul-2018 - 
Hulio Sep-2018 - 
Hyrimoz Jul-2018 Oct-2018 
Imraldi Aug-2017 - 
Solymbic Mar-2017 - 
bevacizumab Avastin® Mvasi Jan-2018 Sep-2017 
Lovenox® Inhixa Sep-2016 - 
 
LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189 with BIOSIMILAR PRODUCT 
INFORMATION, supra note 182.   
 194. Sandoz’s Zarxio is the first biosimilar to be approved and commercialized in the U.S. 
See Siegel & Royzman, supra note 184 and BIOSIMILAR PRODUCT INFORMATION, supra note 
182. 
 195. One in 2006, five in 2007, two in 2008, two in 2009, one in 2010, four in 2013, three 
in 2014, four in 2016, sixteen in 2017, and fifteen in 2018. See supra Table 2. 
 196. Five of nine biosimilars approved in the U.S. were approved in 2017. See infra Table 
2. 
 197. To identify brand name from active substance, see Drugs A-Z List, RXLIST, 
https://www.rxlist.com/drugs/alpha_a.htm (last visited Nov. 3, 2018). 
 198. LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189. 
 199. BIOSIMILAR PRODUCT INFORMATION, supra note 182. 
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Active 
Substance 
Brand 
Name197 
Biosimilar 
Name 
EMA 
Approved198 
FDA 
Approved199 
enoxaparin 
sodium 
Thorinane Sep-2016 - 
epoetin alfa Epogen® 
Abseamed Aug-2007 - 
Binocrit Aug-2007 - 
Epoetin 
Alfa Hexal 
Aug-2007 - 
  
Retacrit Dec-2007 May-2018 
Silapo Dec-2007 - 
etanercept Enbrel® 
Benepali Jan-2016 - 
Erelzi Jun-2017 Aug-2016 
filgrastim Neupogen® 
Accofil Sep-2014 - 
Filgrastim 
Hexal 
Feb-2009 - 
Grastofil Oct-2013 - 
Nivestim Jun-2010 Jul-2018 
Ratiograsti
m 
Sep-2008 - 
Tevagrasti
m 
Sep-2008 - 
Zarzio Feb-2009 Mar-2015 
follitropin alfa Gonal-f® 
Bemfola Mar-2014 - 
Ovaleap Sep-2013 - 
infliximab Remicade® 
Flixabi May-2016 - 
Inflectra Sep-2013 Apr-2016 
Ixifi - Dec-2017 
Remsima Sep-2013 - 
Renflexis - May-2017 
Zessly May-2018 - 
insulin 
glargine Lantus
® 
Abasaglar 
(previously 
Abasria) 
Sep-2014 - 
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Active 
Substance 
Brand 
Name197 
Biosimilar 
Name 
EMA 
Approved198 
FDA 
Approved199 
Lusduna Jan-2017 - 
Semglee Mar-2018 - 
insulin lispro Humalog® 
Insulin 
lispro 
Sanofi 
Jul-2017 - 
pegfilgrastim Heulasta® 
Fulphila Nov-2018 Jun-2018 
Pelgraz Sep-2018 - 
Pelmeg  Nov-2018 - 
Udenyca Sep-2018 Nov-2018 
Ziextenzo  Sep-2018 - 
rituximab Rituxan® 
Blitzima Jul-2017 - 
Ritemvia Jul-2017 - 
Rituzena 
(previously 
Tuxella) 
Jul-2017 
- 
Rixathon Jun-2017 - 
Riximyo Jun-2017 - 
Truxima Feb-2017 Nov-2018 
somatropin Norditropin® Omnitrope Apr-2006 - 
teriparatide Forteo® 
Movymia Jan-2017 - 
Terrosa Jan-2017 - 
trastuzumab Herceptin® 
Herzuma  Feb-2018 Dec-2018 
Kanjinti May-2018 - 
Ogivri - Dec-2017 
Ontruzant Nov-2017 - 
Trazimera Jul-2018 - 
 228 SANTA CLARA LAW REVIEW [Vol:59 
IV. AN ANALYSIS OF WHAT IS SLOWING THE UNITED STATES DOWN 
Of note, all currently approved biosimilars in the EU have approved 
reference biologics that are approved in the US.200  Since the reference 
product has already been approved, the issue is not the safety and 
efficacy profile of the biologic itself.  There is a delay in US approval of 
biosimilars, even though the reference products are long-established.  
The discrepancies between the number of biosimilars approved by the 
FDA versus by the EMA can be explained in a few ways. 
A. Differences Between the EMA and FDA Biosimilar Approval 
Pathways 
First, the EMA has a few more years of experience approving 
biosimilars, as their abbreviated pathway has been in place since 2005.201  
Though the EMA is more seasoned in the biosimilar field, their methods 
of review do not differ much from that of the FDA.202  Furthermore, the 
FDA on average has a shorter review time for marketing authorization 
than the EMA.203  Additionally, biosimilars should have a lower rigor of 
review than original BLAs because they can ride on the coattails of the 
reference product’s safety and efficacy data.  Therefore, the delay is not 
due to protracted FDA review timelines. 
For the Center for Biologics Evaluation and Research (“CBER”),204 
the only area of focused review is manufacturing practices, product 
quality, and interchangeability.  Herein lies one difference between the 
EU and US biosimilar approval process: the FDA pathway offers a 
regulatory designation for interchangeability.205  The EMA, essentially 
a network of the regulatory bodies of its Member States, allows 
 
 200. Reference biologics can be looked up by brand name on the FDA website. See U.S. 
FDA, DRUGS@FDA: FDA APPROVED DRUG PRODUCTS, 
https://www.accessdata.fda.gov/scripts/cder/daf/. 
 201. Schiestl et al., supra note 124. 
 202. Id.  Europe, the USA, and Japan adhere to the International Conference on 
Harmonization Q5E tripartite comparability guidelines. See EUROPEAN MED. AGENCY, ICH 
TOPIC Q5E: COMPARABILITY OF BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS, (June 2005), 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC
500002805.pdf (which outlines considerations for comparability exercises, quality, 
manufacturing process, comparability during development, and nonclinical and clinical 
studies). 
 203. Norman, supra note 42. 
 204. The Center for Biologics Evaluation and Research (CBER) “ensure[s] the safety, 
purity, potency, and effectiveness of biological products including vaccines, blood and blood 
products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of 
human diseases, conditions, or injury.” U.S. FDA, CBER VISION & MISSION, 
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBE
R/ucm122878.htm. 
 205. 42 U.S.C. § 262(k)(4)(B). 
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individual members to adopt the heightened interchangeability 
requirement at the national level.206  
Pursuing interchangeability may be worth adding a transition study, 
but an additional study does increase the approval timelines.  
Interchangeability standards are clearer compared to formulary rules for 
switching patients to “highly similar” biosimilars.207  Theoretically, this 
means that the United States has a longer process for biosimilar 
regulatory approval if there is an incentive to pursue interchangeability 
before approval to engender trust by patients and clinicians for 
substitution. In comparison, the heightened interchangeability 
requirement is incidental in the EMA.208  EU Member States individually 
regulate interchangeability, switching, and substitution.209  Of course, 
information from scientific evaluation performed by EMA’s scientific 
committees can be used to support decisions.210  Nevertheless, the 
member-state level approval does not affect EMA biosimilar approval.  
The impact is downstream, after a biosimilar is already approved.  The 
impact is at the prescription and pharmacy-level, where each member-
state has regulations on how a biosimilar may be used and its insurance 
reimbursement scheme.211  
B. Unfamiliarity with Biosimilars 
Despite the licensure pathway for biosimilars in the US, the 
biosimilar approvals may be slow because of the lack of statutory 
guidance, the higher hurdles of entry as compared to generic products, 
and a general lack of familiarity with biosimilar products.212  Surveyed 
US health care professions expressed safety concerns and the need for 
more evidence before considering biosimilars as acceptable 
alternatives.213  Since FDA biosimilar approval is based on molecular 
similarity, the lessened emphasis on clinical evidence from randomized 
 
 206. Schiestl et al., supra note 124. 
 207. See Stephen Barlas, FDA Guidance on Biosimilar Interchangeability Elicits Diverse 
Views, 42 PHARMACY & THERAPEUTICS 509 (2017). 
 208. EUROPEAN MED. AGENCY, BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR 
HEALTHCARE PROFESSIONALS 29, 
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.p
df (last visited Jan. 30, 2018). 
 209. Id. 
 210. Id. 
 211. Evelien Moorkens et al., Policies for Biosimilar Uptake in Europe: An Overview, 
PLOS ONE (Dec. 28, 2017), 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190147. 
 212. Ralph Boccia et al., Can Biosimilars Help Achieve the Goals of US Health Care 
Reform?, 9 CANCER MGMT. & RES. 197 (June 1, 2017),  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459961/. 
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trials raises concerns about immunologic effects, especially if a 
prescriber were to switch a patient from the standard of care to a 
biosimilar.214 Approved interchangeable products could alleviate these 
concerns. However, no biosimilar has yet been designated as 
interchangeable in the US.215 
C. Patent Rights Affecting Approval Timelines 
Patent litigation could also be slowing down the FDA process.  
Companies can market approved biosimilars after the reference 
medicine market protection expires after about ten years.216  As of 2017, 
thirty-seven biosimilars are approved by the EMA. In the US, 
biosimilars will not be approved until twelve years after the date a 
reference product was first licensed.217 
 In 2015, the Supreme Court by unanimous decision in Sandoz v. 
Amgen paved the way for the first biosimilar approval in the US.218  
Sandoz produced Zarxio (filgrastim) with the intention of marketing 
Zarxio with Amgen’s Neupogen as the reference product, in accordance 
to the BPCIA.219  The FDA accepted Sandoz’s application for review.  
Sandoz then gave notice to Amgen of its intent to market Zarxio 
immediately upon FDA approval.220  Blindsided, Amgen sued Sandoz 
for violations of the BPCIA, which included Sandoz’s failure to provide 
notice of commercial marketing under § 262(l)(8)(A) prior to obtaining 
licensure from the FDA.221  “Section 262(l) (8)(A) contains a single 
timing requirement: The applicant must provide notice at least 180 days 
prior to marketing its biosimilar.”222  There is no reference in the 
applicable statute to a notification timing requirement prior to FDA 
licensure.  By not creating an artificial marketing delay for approved 
biosimilars, the Court created a profit motive for biosimilar marketers.  
In theory, Sandoz should expedite the timelines for biosimilars to hit the 
market, but the effects remain yet to be seen. 
 
 214. Id. 
 215. Joshua Cohen, What’s Holding Back Market Uptake of Biosimilars?, FORBES, June 
29, 2018, https://www.forbes.com/sites/joshuacohen/2018/06/20/whats-holding-back-
market-uptake-of-biosimilars/#12f060f9691a. 
 216. EUROPEAN MED. AGENCY, BIOSIMILARS IN THE EU: INFORMATION GUIDE FOR 
HEALTHCARE PROFESSIONALS 28 (2017), 
https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-
professionals_en.pdf.   
 217. 42 U.S.C. § 262(k)(7)(A). 
 218. See Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017). 
 219. Id. at 1666. 
 220. Id. 
 221. Id. at 1667. 
 222. Id. at 1677. 
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Notably, like the EU regulatory scheme, the BPCIA does not allow 
a sponsor to renew data exclusivity due to changes in drug strength, 
formulation, or route of administration.223  This is to prevent arbitrary 
formulary changes that act as a pretext for extending the data exclusivity 
period.  However, the BPCIA does allow for “second-generation 
biological product with structural modifications” that changes the safety, 
purity, or potency of the original product.224  Such restrictions on a 
sponsor’s data exclusivity should promote biosimilars approval. 
D. A Case Study: The FDA Rejects Pfizer’s Epoetin Biosimilar 
Epoetin alfa is an injectable drug that treats anemia associated with 
chronic kidney failure, including patients that are receiving dialysis.225  
It works by stimulating the bone marrow to produce red blood cells.  It 
is a treatment, not a cure, and is used indefinitely.226  
In an FDA Briefing Document posted May 25, 2017 prior to an 
advisory committee meeting, FDA reviewers lauded Pfizer’s epoetin 
alfa biosimilar “Epoetin Hospira” as being “highly similar” to Amgen’s 
Epogen based on the totality of analytical data.227  Surprisingly, despite 
the endorsement from the FDA staff and an advisory committee, Pfizer’s 
biosimilar for Amgen’s Epogen was rejected a second time.228  The crux 
of the issue was a fill-finish plant that was acquired by Pfizer with their 
acquisition of Hospira. 229  The BLA listed this plant as a potential 
manufacturing site for the proposed biosimilar,230 although it was subject 
to four warning letters in a four year period.231  Other manufacturing sites 
within the same network were cited for CGMP violations too.232  This 
 
 223. Gitter, supra note 165, at 591. 
 224. Id. 
 225. Omudhome Ogbru, Epoetin Alfa, MEDICINENET.COM, 
https://www.medicinenet.com/epoetin_alfa/article.htm#what_is_the_dosage_for_epoetin_alf
a? (last visited Jan. 30, 2018). 
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 227. U.S. FDA, FDA BRIEFING DOCUMENT, ONCOLOGIC DRUGS ADVISORY COMMITTEE 
MEETING, BLA 125545 “EPOETIN HOSPIRA,” A PROPOSED BIOSIMILAR TO EPOGEN/PROCRIT 
(EPOETIN ALFA) (May 25, 2017), 
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/
OncologicDrugsAdvisoryCommittee/UCM559967.pdf. 
 228. Eric Palmer, FDA Rejects Pfizer’s Epogen Biosimilar for the Second Time, 
FIERCEPHARMA (June 22, 2017), https://www.fiercepharma.com/regulatory/fda-rejects-
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 231. Palmer, supra note 228. 
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unexpected rejection is expected to delay Epoetin Hospira through 
2018.233  In contrast, Binocrit, the first epoetin alfa biosimilar, was 
approved by the EMA in 2007, over ten years ago.234 
Since Binocrit was approved over a decade ago, it does not seem 
that there are misgivings about the safety and efficacy of the product 
itself.  The variable affecting its rejection was manufacturing practices 
that were not compliant with relevant regulation.  This surprising 
rejection illustrates that manufacturing fidelity is a key component to 
biosimilar approval.  Now, with the US mutually recognizing EU-
approved manufacturing sites as compliant, perhaps there is a way for 
the US to accept the biosimilars that are produced at those sites.  
V. EU-APPROVED BIOSIMILARS COULD PAVE THE WAY FOR 
APPROVALS IN THE UNITED STATES 
A. Mutual Recognition of Manufacturing Inspections Does Make 
Mutual Recognition of Biosimilars Feasible 
One justification for the 2017 Amendment to the US-EU MRA was 
to better allocate resources for the benefit of patient safety and public 
health.235  The MRA aimed to reduce duplicative work while still 
recognizing the FDA and EU’s regulatory autonomy by keeping the door 
open to inspections as needed.236  
The FDA could easily take advantage of this new efficiency.  In the 
case of epoetin alpha above, the FDA could grant access to epoetin alfa 
biosimilars already approved in the EMA.  Given that the bottleneck of 
the biosimilar approval process is manufacturing assurances, accepting 
existing data from the EMA will expedite the FDA review process.  
Biosimilars that reference a biologic that has been on the market for a 
long time should face no obstacle in terms of patent rights.  Furthermore, 
biosimilars that have been on the European market for years should have 
fewer quality, efficacy, and safety concerns because it has the benefit of 
post-market monitoring.237  If the MRA could be applied to biosimilar 
review and approval, the US would be a step closer to a more 
competitive and affordable biologics market. 
 
 
 233. Id. 
 234. LIST OF BIOSIMILARS APPROVED BY THE EMA, supra note 189. 
 235. FAQ / THE MUTUAL RECOGNITION AGREEMENT, supra note 166. 
 236. Id. 
 237. As discussed in supra Part II.E, post-market drug use by a larger patient population 
will yield aggregate epidemiological data that may not have been observed during a clinical 
trial’s limited time period and scope. 
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B. Some Countries Already Mutually Recognize Third-Party Data for 
Assessment Purposes… 
Mutual recognition of assessment and inspection results is not a 
novel concept.  There are non-EU regulatory authorities that base their 
market approvals on EU assessments.238  Switzerland, for example, will 
make a medicinal product already authorized in another country readily 
available to its patient population as rapidly as possible.239  This has 
reduced new product review time by up to twenty percent.240  This 
example highlights a generous application of the mutual recognition 
doctrine.  Admittedly, Switzerland’s deference to a mutual recognition 
regulatory standard is colored by Switzerland’s special relationship with 
the EU.  Like EU-member countries, the Swiss-EU relationship is 
motivated by economic protectionism.241  The US does not have such a 
relationship with the EU.  Thus, a mutual recognition model like 
Switzerland’s is too deferential to EMA authority to be a possibility in 
the US.  
Perhaps a more conservative model is the International Generic 
Drug Regulators Programme (“IGDRP”),242 which launched an 
information-sharing pilot in 2014 to enable mutual recognition of 
generic drugs across participating countries.243  In addition to the EU 
authorities, participants include regulatory authorities for Canada 
(Health Canada), Switzerland (Swissmedic), Taiwan (Taiwan Food and 
Drug Administration), and Australia (Therapeutic Goods 
Administration).244  IGDRP utilized the EU decentralized procedure to 
model their initiative.245  As discussed above, under the decentralized 
procedure Member States adopt mutual recognition of medicines that 
have not previously received marketing authorization by relying on the 
national authorization granted by one Member State.246  Here, the 
participating members agreed to converge their regulatory standards so 
that drugs approved in one participating country has a pathway for 
 
 238. Luigetti et al., supra note 104, at 562. 
 239. Id. at 563. 
 240. Id. 
 241. Switzerland’s economic and trade relations with the EU are governed through a series 
of bilateral agreements, which grants Switzerland access to the EU’s single market.  The EU 
is Switzerland’s main trading partner.  See EUROPEAN COMM’N, COUNTRIES AND REGIONS: 
SWITZERLAND, http://ec.europa.eu/trade/policy/countries-and-regions/countries/switzerland/ 
(last updated Apr. 16, 2018). 
 242. International Generic Drug Regulators Programme was launched to increase 
efficiency in generic drug review. 
 243. Luigetti et al., supra note 104, at 561. 
 244. Id. 
 245. Directive 2004/27/EC outlines the decentralized procedure for marketing 
authorization.  See Directive 2004/27/EC, O.J. (L 136/44), art. 24. 
 246. Procedure discussed supra Part II.B.3. 
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authorization in another country without duplicating effort.247  The 
program stated that promoting generic drug availability was a goal, even 
though the program excluded biosimilars.248  However, because 
biosimilars are analogous to generics—they are reproductions of an 
approved reference product with an established safety and efficacy 
record—recognition of biosimilars among IGDRP participants could 
follow the same procedure.  Likewise, the US could also participate in 
such a program.  However, because the FDA was founded upon 
consumer protection principles (as opposed to the EMA’s economic 
protection principles),249 basing approvals off other countries’ 
evaluations sacrifices too much regulatory authority.  This is a huge 
jump from merely accepting multinational data as a supplement to an 
approval. 
The FDA will use, where appropriate, foreign reviews to 
supplement its evaluation of a product for market authorization.250  As 
clinical research is becoming increasingly global the FDA recognizes 
that sponsors may conduct multinational clinical studies.251  When the 
foreign clinical study is not conducted under an IND, the sponsor must 
ensure that the study complies with the requirements in 21 C.F.R. § 
312.120252 for the data to qualify for marketing approval.253  The study 
must produce data that can be validated by the FDA and study sites must 
be open to onsite inspection if necessary.254 
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C. …But the FDA Indicates that Interchangeability Comparators 
Should be US-Approved 
Accepting multinational clinical data as a supplement to a 
marketing approval application still allows the FDA to retain regulatory 
autonomy.  The FDA could also accept supplemental clinical data for 
proposed biosimilars.  In comparison, the EMA accepts data for 
biosimilars that were compared with foreign-approved biologics as long 
as there are bridging studies that compare the foreign-approved biologic 
with the locally licensed version.255  To an extent, the FDA will accept 
comparison study data for highly similar biologics, but the FDA stops 
short of allowing foreign comparator products to be used to demonstrate 
interchangeability.256  As discussed above, interchangeability is 
effectively mandatory in the US market.257 
In January 2017, the FDA published the long-awaited draft 
guidance for industry titled “Considerations in Demonstrating 
Interchangeability With a Reference Product.”258  Of note, the draft 
guidance document states that a non-US-licensed comparator may be 
used for purposes of demonstrating biosimilarity, but “using a non-US-
licensed comparator product generally would not be appropriate” in a 
switching study supporting a determination of interchangeability.259  
Switching studies are designed to assess whether switching between a 
comparator and the proposed biosimilar will affect the immune system’s 
response once the switch occurs.260  A non-US-licensed comparator 
product could have subtle differences with a US-licensed comparator 
product.261  Results from a switching study using a non-US-licensed 
comparator product would lead to uncertainty about the cause of any 
immunologic responses.262 
However, the US-licensed comparator requirement does not detract 
from the US-EU MRA’s potential to give EU-approved biosimilars a 
pathway for US approval, even under heightened interchangeability 
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requirements.  All the EMA-approved biosimilars have US-approved 
biologic reference products.263  EMA-approved biosimilars that were 
approved based on comparator studies with a US-approved biologic 
reference product can still qualify under the FDA draft guidance.  In that 
scenario, switching studies meeting the FDA criteria have already been 
completed, albeit in another country. 
D. Complete Mutual Recognition of Approved Products is Likely Not 
Realistic… 
Complete mutual recognition of approved products has been 
proposed as clinical development of novel therapies become 
increasingly globalized.  However, the legal frameworks of each 
Member State of the EMA and the FDA are too much to untangle 
anytime soon.264  The healthcare systems are so vastly different, meaning 
that there are differing levels of motivations to use biosimilars as a 
medicine price control scheme.  The EU, with a more socialized 
healthcare approach, is incentivized to drive down the costs of 
therapeutic products, sometimes by implementing government-set prices 
in order to achieve that objective.265  For the US, the BPCIA as part of 
the Affordable Care Act is slowly driving the US towards approving 
more biosimilars.  But the biosimilar approval pathway shows a uniquely 
American concern for patent rights: developers are granted twelve years 
of market exclusivity for new biologics, but future access to these high 
cost drugs is encouraged by allowing entrants to compete after 
exclusivity and patent expiration.266 
Ultimately, the discrepancy in the approach to biosimilars is 
because the FDA and EMA were founded on different principles.  The 
FDA originated as a consumer protection agency.267  The EMA was born 
from the EU as a market protection initiative.268  Different origin stories 
do inform their respective openness to mutual recognition procedures: 
the FDA has a tradition of autonomy and a long-history of increasingly 
discerning scientific standards, which could mean that it is wary of 
trusting other agencies, even the EMA, to do its work.  In contrast, the 
EMA has a tradition of fostering collaboration amongst its country 
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participants, meaning it was built on mutual recognition procedures 
between Member States of the EU and other countries in the European 
Economic Area. 
E. …But Biosimilars are a Good Start towards International 
Harmonization 
Variation in the biologics manufacturing processes exist for reasons 
such as “scaling up of the process, improving efficiency, or 
modernization when equipment needs to be updated or replaced.”269  “To 
allow such manufacturing changes to occur without the need for 
companies to conduct a new clinical development program, regulators 
devised the comparability concept to establish whether the pre- and 
postchange [sic] products were sufficiently similar to permit ongoing 
marketing under the same product label.”270  As such, with the step that 
the FDA and EMA have now taken to align their manufacturing 
standards, any misgivings that the FDA may have to an EMA-approved 
biosimilar can be resolved via the comparability scheme. 
A change to the manufacturing process must always be approved 
by regulators.  Analytical and functional data is usually sufficient for 
continued approval of the biosimilar.  In rare cases, additional clinical 
studies need be done to demonstrate no impact on quality, safety, and 
efficacy.271  Here, it logically follows that the FDA could move towards 
developing a means to grant authorization to a requesting manufacturer 
that is already producing an EMA-approved biosimilar.  Any concerns 
about the safety and efficacy of the EMA-approved biosimilar can be 
addressed by invoking the right to conduct supplementary inspections, a 
right reserved in the 2017 Amended US-EU MRA. 
VI. CONCLUSION 
Instead of being years behind, the United States’ biosimilars 
initiative could be ramped up so that the market for biosimilars in the 
United States is comparable to the European Union’s.  The FDA 
releasing a formal guidance on interchangeability requirements certainly 
will clear some regulatory uncertainty in the US.  Additionally, the 
Mutual Recognition Agreement for manufacturing inspections presents 
a great opportunity for the FDA to approve a wider range of biosimilars 
whose manufacturing practices are deemed compliant by the EU.  After 
the United States validates EU manufacturing sites on a national 
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member-state level, the US could approve biosimilars produced at those 
approved sites.   
The next step is for the FDA to build upon the agreement and work 
towards recognizing that the biosimilars that are manufactured under 
robust EMA guidelines are fit for approval in the United States too.  By 
approving more biosimilars in the US, competition increases in the 
biologics market, which will drive down drug costs, which is analogous 
to the effect that generic product availability has on drug pricing.  This 
is important because biologics are prone to price markup.  Unlike 
traditional drugs, biologics are genetically engineered from cell cultures, 
which do make them costlier to produce.  Additionally, biologics are 
typically delivered intravenously or subcutaneously.272  “[T]he markup 
of an infused medicine is greater in an inpatient setting than in a 
physician office, providing an incentive for institutions able to 
administer drugs in a setting that qualifies as inpatient.”273  
Of course, there are misgivings from the private sector, as 
demonstrated by the current biosimilar litigation landscape, but existing 
patent-exclusivity periods exist to remedy those concerns.  Admittedly, 
the outcome of patent litigation over manufacturing techniques could 
greatly affect biosimilar survival to market.274  Nevertheless, much-
needed, long-established therapies should not be held hostage to a 
bureaucratically drawn-out approval process. 
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